The Pharmaceuticals Division of Novartis is recognized worldwide for the innovative medicines we provide to patients, physicians and healthcare organizations.
This growing business develops and markets patent-protected prescription drugs for important health needs. Our products are concentrated in major therapeutic areas: Cardiovascular/Metabolism, Oncology, Neuroscience, Dermatology, Arthritis Bone, Respiritory, Infectious Disease, Transplant, Opthalmics, GI, Urinary.
We have received 15 new pharmaceutical product approvals in the US since 2000, the most of any pharmaceutical company. Our current product portfolio includes more than 45 key marketed products, many of which are leaders in their respective therapeutic areas. The product development pipeline involves nearly 140 projects – including potential new products as well as potential new indications or formulations for existing products – in various stages of clinical development.
Industry experts have ranked Novartis as a leader for having one of the best combinations of organic growth, pipeline opportunities, and low patent-risk exposure among major companies in the pharmaceuticals industry